LBI-HTA - Publications - Search - Gefitinib (Iressa®) for the first-line treatment of non-small cell lung cancer

Nachtnebel, A. (2010): Gefitinib (Iressa®) for the first-line treatment of non-small cell lung cancer . DSD: Horizon Scanning in Oncology 06.

[img]PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader
252Kb
Abstract

Despite data indicating that patients suffering from non-small cell lung cancer with EGFR mutations might benefit from first-line therapy with gefitinib, several unresolved issues make it difficult to judge its final clinical value. Phase III studies were conducted in a population not representative for a Caucasian population and challenges remain in the determination of EGFR status.

Item Type:DSD: Horizon Scanning in Oncology
Keywords:non-small cell lung cancer, NSCLC, gefitinib, Iressa, oncology
Subjects:QZ Pathology > QZ 200-380 Neoplasms.Cysts
WF Respiratory system
Language:English
Series Name:DSD: Horizon Scanning in Oncology 06
Deposited on:28 Jan 2010 20:35
Last Modified:28 Jan 2010 20:35

Repository Staff Only: item control page